There is a certain electricity in biotech when a company stops whispering at the edges of innovation and steps into the room like it owns the air. TRIANA Biomedicines just delivered that moment with a $120M Series B that pulled in Ascenta Capital and Bessemer Venture Partners as co-leads, backed by new believers from YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures. The returning syndicate from RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, and Surveyor Capital did not come back out of nostalgia. They came back because TRIANA Biomedicines is building something that turns undruggable targets into solvable problems, and investors recognize when the signal is stronger than the noise.
The evolution from a 2019 founding to a 2025 oversubscribed round has the same narrative tension you find in a great Isaacson biography. Co-founder & CEO Patrick Trojer brought the kind of strategic patience learned from building Constellation Pharmaceuticals into a $1.7B acquisition. Co-founder Jesse Chen may have shifted into an advisor role in 2024, but his early platform architecture still sits at the core of TRIANA Biomedicines’ identity. This is not a company chasing trends. This is a company designing the next generation of targeted protein degradation by understanding why 85% of disease targets have historically laughed in the face of small molecules.
What makes TRIANA Biomedicines compelling is how the company treats drug discovery like a matchmaking service with consequences. Its target-first and proximity-first molecular glue engine scans 600+ E3 ligases to find the right pairing for a disease driver, then builds chemical possibilities around that biology with structural insights, bespoke libraries, and computational horsepower. When a platform like that catches Pfizer’s attention to the tune of $49M upfront and more than $1.5B in potential milestones, you start to understand why this Series B turned heads across the ecosystem.
The lead program, TRI-611, is aiming at ALK+ NSCLC with a degrader built to knock down resistant mutations and cross into the CNS where many TKIs stall. With Ileana Germa steering clinical development, Victor Palombella shaping scientific direction, and Eric Plamondon driving manufacturing precision, the move toward IND and first-in-human studies feels less like a gamble and more like a company stepping confidently into its next chapter.
Funding rounds of this size are never luck. They are earned through credibility, clarity, and a team that knows how to turn raw science into real-world impact. TRIANA Biomedicines is not just aiming to expand oncology options. It is positioning itself as one of the few players capable of redefining what is possible in TPD and beyond.
Startups Startup Funding Venture Capital Series B Biopharmaceutical Biotech Pharmaceutical Healthcare HealthTech Technology Innovation Tech Ecosystem Startup Ecosystem
